Trubion Investor Sues To Halt $135M Sale To Emergent
A Trubion Pharmaceuticals Inc. investor has filed a putative class action in an effort to block the $135.5 million sale of the company to Emergent BioSolutions Inc., claiming that the proposed...To view the full article, register now.
Already a subscriber? Click here to view full article